montelukast organon 4 mg
n.v. organon, holandsko - montelukast - 14 - bronchodilatantia, antiasthmatica
monkasta 10 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - montelukast - 14 - bronchodilatantia, antiasthmatica
monkasta 4 mg žuvacie tablety
krka, d.d., novo mesto, slovinsko - montelukast - 14 - bronchodilatantia, antiasthmatica
monkasta 5 mg žuvacie tablety
krka, d.d., novo mesto, slovinsko - montelukast - 14 - bronchodilatantia, antiasthmatica
belokast 5 mg
belupo, s.r.o., slovensko - montelukast - 14 - bronchodilatantia, antiasthmatica
belokast 10 mg
belupo, s.r.o., slovensko - montelukast - 14 - bronchodilatantia, antiasthmatica
montelukast organon 10 mg
n.v. organon, holandsko - montelukast - 14 - bronchodilatantia, antiasthmatica
montelukast organon 5 mg
n.v. organon, holandsko - montelukast - 14 - bronchodilatantia, antiasthmatica
montelukast medreg 10 mg filmom obalené tablety
medreg s.r.o., Česká republika - montelukast - 14 - bronchodilatantia, antiasthmatica
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastické činidlá - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.